FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML

Yannan Jia; Weiguo Zhang; Mahesh Basyal; Kyung Hee Chang; Lauren Ostermann; Jared K. Burks; Charlie Ly; Hong Mu-Mosley; Qi Zhang; Xin Han; William E. Fogler; John L. Magnani; Arnaud Lesegretain; Anna A. Zal; Tomasz Zal; Michael Andreeff

doi:10.1038/s41375-023-01897-x

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML

Yannan Jia, Weiguo Zhang, Mahesh Basyal, Kyung Hee Chang, Lauren Ostermann, Jared K. Burks, Charlie Ly, Hong Mu-Mosley, Qi Zhang, Xin Han, William E. Fogler, John L. Magnani, Arnaud Lesegretain, Anna A. Zal, Tomasz Zal, Michael Andreeff

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	1379-1383
Number of pages	5
Journal	Leukemia
Volume	37
Issue number	6
DOIs	https://doi.org/10.1038/s41375-023-01897-x
State	Published - Jun 2023

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-023-01897-x

Cite this

Jia, Y., Zhang, W., Basyal, M., Chang, K. H., Ostermann, L., Burks, J. K., Ly, C., Mu-Mosley, H., Zhang, Q., Han, X., Fogler, W. E., Magnani, J. L., Lesegretain, A., Zal, A. A., Zal, T., & Andreeff, M. (2023). FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia, 37(6), 1379-1383. https://doi.org/10.1038/s41375-023-01897-x

Jia, Y, Zhang, W, Basyal, M, Chang, KH, Ostermann, L, Burks, JK, Ly, C, Mu-Mosley, H, Zhang, Q , Han, X, Fogler, WE, Magnani, JL, Lesegretain, A, Zal, AA, Zal, T & Andreeff, M 2023, 'FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML', Leukemia, vol. 37, no. 6, pp. 1379-1383. https://doi.org/10.1038/s41375-023-01897-x

@article{8e5ccc7f05ed45bfb03f8e78d36b7abb,

title = "FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML",

author = "Yannan Jia and Weiguo Zhang and Mahesh Basyal and Chang, {Kyung Hee} and Lauren Ostermann and Burks, {Jared K.} and Charlie Ly and Hong Mu-Mosley and Qi Zhang and Xin Han and Fogler, {William E.} and Magnani, {John L.} and Arnaud Lesegretain and Zal, {Anna A.} and Tomasz Zal and Michael Andreeff",

note = "Funding Information: This study was supported in part by the National Institutes of Health through The University of Texas Anderson{\textquoteright}s Cancer Center Support Grant (P30 CA016672), The University of Texas MD Anderson Cancer Moon Shots Program (MDS/AML program), and the Paul & Mary Haas Endowment (Chair in Genetics). Research funding support was also received from GlycoMimetics, Daiichi Sankyo, and the Chinese Academy of Medical Sciences & Peking Union Medical College{\textquoteright}s Institute of Hematology & Hospital of Blood Diseases. The authors would like to thank Editing Services, Research Medical Library, The University of Texas M.D. Anderson Cancer Center for providing critical reviews and editorial assistance in the preparation of this manuscript. ",

year = "2023",

month = jun,

doi = "10.1038/s41375-023-01897-x",

language = "English (US)",

volume = "37",

pages = "1379--1383",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML

AU - Jia, Yannan

AU - Zhang, Weiguo

AU - Basyal, Mahesh

AU - Chang, Kyung Hee

AU - Ostermann, Lauren

AU - Burks, Jared K.

AU - Ly, Charlie

AU - Mu-Mosley, Hong

AU - Zhang, Qi

AU - Han, Xin

AU - Fogler, William E.

AU - Magnani, John L.

AU - Lesegretain, Arnaud

AU - Zal, Anna A.

AU - Zal, Tomasz

AU - Andreeff, Michael

N1 - Funding Information: This study was supported in part by the National Institutes of Health through The University of Texas Anderson’s Cancer Center Support Grant (P30 CA016672), The University of Texas MD Anderson Cancer Moon Shots Program (MDS/AML program), and the Paul & Mary Haas Endowment (Chair in Genetics). Research funding support was also received from GlycoMimetics, Daiichi Sankyo, and the Chinese Academy of Medical Sciences & Peking Union Medical College’s Institute of Hematology & Hospital of Blood Diseases. The authors would like to thank Editing Services, Research Medical Library, The University of Texas M.D. Anderson Cancer Center for providing critical reviews and editorial assistance in the preparation of this manuscript.

PY - 2023/6

Y1 - 2023/6

UR - http://www.scopus.com/inward/record.url?scp=85153096084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85153096084&partnerID=8YFLogxK

U2 - 10.1038/s41375-023-01897-x

DO - 10.1038/s41375-023-01897-x

M3 - Article

C2 - 37085610

AN - SCOPUS:85153096084

SN - 0887-6924

VL - 37

SP - 1379

EP - 1383

JO - Leukemia

JF - Leukemia

IS - 6

ER -

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this